Inimmune
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Immunology
Inimmune is made up of a team of innate immunodulation experts developing next generation immunotherapies the treatment of allergy and inflammation.
Company HQ City:
Missoula
Company HQ State:
Montana
Company HQ Country:
United States
Year Founded:
2016
Lead Product in Development:
INI-2004 intranasal spray is a disease modifying treatment for allergic rhinitis, but is applicable to all allergies.
CEO
David Burkhart
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
May to June 2026
What is your next catalyst (value inflection) update?
Phase 2 topline data from our allergic rhinitis trial with INI-2004
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}